<i>Leishmania</i> Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients

<i>Leishmania</i> Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients

Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the one side, this drug can rapidly improve the symptoms related to the hematological disease; on the other side, the inhibition of JAK1/2 can lead to immunosuppression which may increase the risk of infectio...

Full description

Bibliographic Details
Main Authors: Andrea Duminuco, Salvatore Scarso, Alessandra Cupri, Nunziatina Laura Parrinello, Loredana Villari, Grazia Scuderi, Giuliana Giunta, Salvatore Leotta, Giulio Antonio Milone, Giulia Giuffrida, Giuseppe Alberto Palumbo, Giuseppe Milone
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Journal of Clinical Medicine
Subjects:
<i>Leishmania</i>
ruxolitinib
myelofibrosis
immune response
cytokines
Online Access:https://www.mdpi.com/2077-0383/12/2/578

Internet

https://www.mdpi.com/2077-0383/12/2/578

Similar Items